Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Tonix Pharmaceuticals (NASDAQ:TNXP) from a hold rating to a sell rating in a research report released on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Tonix Pharmaceuticals Stock Performance

Shares of NASDAQ:TNXP opened at $12.88 on Friday. The company’s fifty day moving average is $15.42 and its two-hundred day moving average is $17.97. Tonix Pharmaceuticals has a 1-year low of $12.70 and a 1-year high of $69.97. The stock has a market capitalization of $172.66 million, a price-to-earnings ratio of -0.90 and a beta of 1.88.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings results on Thursday, March 12th. The company reported ($3.98) EPS for the quarter, missing the consensus estimate of ($3.16) by ($0.82). Tonix Pharmaceuticals had a negative net margin of 946.22% and a negative return on equity of 60.15%. The business had revenue of $5.39 million during the quarter, compared to analyst estimates of $2.97 million. Sell-side analysts expect that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Insider Activity at Tonix Pharmaceuticals

In other news, CEO Seth Lederman acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 18th. The shares were acquired at an average price of $14.89 per share, with a total value of $223,350.00. Following the acquisition, the chief executive officer directly owned 15,001 shares in the company, valued at approximately $223,364.89. The trade was a 1,500,000.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.03% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of TNXP. Legal & General Group Plc bought a new position in Tonix Pharmaceuticals in the 2nd quarter worth about $25,000. State of Wyoming bought a new stake in shares of Tonix Pharmaceuticals during the fourth quarter valued at approximately $27,000. Ameritas Investment Partners Inc. bought a new stake in shares of Tonix Pharmaceuticals during the second quarter valued at approximately $28,000. Russell Investments Group Ltd. acquired a new position in shares of Tonix Pharmaceuticals during the third quarter worth approximately $29,000. Finally, Police & Firemen s Retirement System of New Jersey bought a new position in Tonix Pharmaceuticals in the 2nd quarter worth approximately $62,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Key Tonix Pharmaceuticals News

Here are the key news stories impacting Tonix Pharmaceuticals this week:

• Positive Sentiment: First participant dosed in a Phase 1 investigator‑initiated pharmacodynamic study of TNX‑1900 to assess potential for treating migraine and craniofacial pain; intranasal oxytocin blocks CGRP release in animal models and represents a mechanism distinct from current CGRP drugs, which could broaden Tonix’s pipeline if signals are positive. Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900
• Neutral Sentiment: Multiple outlets (Business Insider, Yahoo Finance, TipRanks) picked up the dosing announcement — that raises visibility and investor attention but the study is early‑stage (pharmacodynamic model), so clinical readouts and commercialization remain uncertain. Tonix Pharmaceuticals Announces First Participant Dosed (Business Insider)
• Negative Sentiment: Zacks Research substantially lowered its near‑term EPS forecasts for Tonix, cutting FY2026 and FY2027 estimates and issuing much larger expected losses per share (e.g., FY2026 now modeled at roughly -$10.52). Those revisions signal analyst concern about cash runway, development timelines and the likelihood of future dilution — a key reason for downward pressure on the stock. What is Zacks Research’s Estimate for TNXP FY2028 Earnings?

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.